CoDa Series B Brings in $19.2M for Venous Leg Ulcer Phase II
By Tom Wall
Tuesday, April 19, 2011
San Diego-based CoDa Therapeutics Inc. raised $19.2 million in a Series B financing, allowing the biotech to a push forward with a large Phase II multicenter venous leg ulcer trial with Nexagon, its lead product for chronic wound patients.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.